Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Jagsonpal-Pharma"

8 News Found

Jagsonpal Pharmaceuticals launches QueeZy-ER
News | March 09, 2024

Jagsonpal Pharmaceuticals launches QueeZy-ER

The product combines proven efficacy of Doxylamine succinate 20 mg and Pyridoxine hydrochloride 20 mg in an Extended Release formulation


Jagsonpal Pharmaceuticals posts Q1 FY2024 PAT at Rs. 7.47 Cr
News | August 03, 2023

Jagsonpal Pharmaceuticals posts Q1 FY2024 PAT at Rs. 7.47 Cr

The company has reported total income of Rs. 62.15 crores during the period ended June 30, 2023


Jagsonpal Pharmaceuticals reports Q2FY23 net profit at Rs. 10.41 Cr
News | November 11, 2022

Jagsonpal Pharmaceuticals reports Q2FY23 net profit at Rs. 10.41 Cr

The company has reported total income of Rs. 61.64 crores during the period ended September 30, 2022.


Jagsonpal Pharmaceuticals appoints Manish Gupta as the MD
People | July 18, 2022

Jagsonpal Pharmaceuticals appoints Manish Gupta as the MD

Manish led SeQuent since 2014 and played a major role in transforming the company


Infinity Holding Group to acquire 43.7 per cent stake in Jagsonpal Pharma
News | February 22, 2022

Infinity Holding Group to acquire 43.7 per cent stake in Jagsonpal Pharma

The transaction as well as the open offer is expected to be completed by June this year.


Jagsonpal Pharma inks agreement with Suvinys Developers
News | February 19, 2022

Jagsonpal Pharma inks agreement with Suvinys Developers

Suvinys Developers will supply dydrogesterone to Jagsonpal Pharma as per the terms and conditions mentioned in the agreement.


Jagsonpal Q3 FY23 revenues grew by 11.6% to Rs. 60.1 Cr; PAT up by 47.1%
News | February 09, 2023

Jagsonpal Q3 FY23 revenues grew by 11.6% to Rs. 60.1 Cr; PAT up by 47.1%

Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore


Reasons for the surge in M& A in healthcare and pharmaceutical sectors in India: Ankit Poddar & Navroz Mahudawala, Candle Partners
Opinion | September 22, 2022

Reasons for the surge in M& A in healthcare and pharmaceutical sectors in India: Ankit Poddar & Navroz Mahudawala, Candle Partners

Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.